| Literature DB >> 27922598 |
S Charmsaz1,2,3, F Al-Ejeh4, T M Yeadon1, K J Miller1, F M Smith1, B W Stringer1, A S Moore5, F-T Lee6, L T Cooper1, C Stylianou1, G T Yarranton7, J Woronicz7, A M Scott6, M Lackmann8, A W Boyd1,2.
Abstract
The human EphA3 gene was discovered in a pre-B acute lymphoblastic leukemia (pre-B-ALL) using the EphA3-specific monoclonal antibody (mAb), IIIA4, which binds and activates both human and mouse EphA3. We use two models of human pre-B-ALL to examine EphA3 function, demonstrating effects on pre-B-cell receptor signaling. In therapeutic targeting studies, we demonstrated antitumor effects of the IIIA4 mAb in EphA3-expressing leukemic xenografts and no antitumor effect in the xenografts with no EphA3 expression providing evidence that EphA3 is a functional therapeutic target in pre-B-ALL. Here we show that the therapeutic effect of the anti-EphA3 antibody was greatly enhanced by adding an α-particle-emitting 213Bismuth payload.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27922598 DOI： 10.1038/leu.2016.371
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528